CTLA4 and hypophysitis: The higher risk of hypophysitis when treated with ipilimumab can be explained by the fact that anti CTLA-4 therapy can stimulate autoreactive T cells, as well as leading to the production of antibodies directed against pituitary antigens, infiltrating the gland tissue and increasing complement activation, which has been demonstrated in animal models [49].